• 6 min read
• Published on 11 July 2025
Listen to article
6:38Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Let's be frank. For decades, the field of Alzheimer's research has been a graveyard for investor capital. Billions have been poured into promising drugs only to see them fail spectacularly in late-stage trials. So, when news of another "breakthrough" hits my desk, my default setting is a healthy, world-weary scepticism. But this time, I must admit, things feel different. The recent FDA approval for a safer dosing of Eli Lilly’s drug isn't just another headline. It feels like a genuine crack in the dam.
What has my cynical eyebrow raised, you ask? It’s not just that the drugs work, it’s how they can now be used. The big bogeyman for these anti-amyloid therapies has always been a nasty side effect involving brain swelling. It made doctors hesitant and limited the pool of eligible patients. The new, gradual dosing protocol slashes that risk significantly. To me, this is the real story. It’s the difference between having a brilliant race car that’s too dangerous for most to drive, and one that’s suddenly safe enough for the open road. The potential market for these treatments may have just expanded enormously, and that’s something any investor should note.
Eli Lilly and Company (LLY) is, for now, the name on everyone’s lips. By securing the first approval for this safer method, they’ve gained a powerful head start. According to research from Nemo, the financial implications are staggering, with a potential market of millions of patients. But this is hardly a one-horse race. Biogen Inc. (BIIB), their chief rival, is already in the market. While Lilly’s safety win puts the pressure on, Biogen’s presence actually validates the entire scientific approach. This competition could fuel innovation, which is often good for the sector as a whole. It’s not just about picking one winner, but understanding the tide that could lift several boats. Beyond these titans, smaller clinical-stage firms like Anavex Life Sciences Corp (AVXL) now find themselves in a much more interesting position, offering a higher-risk but potentially higher-reward path for those with the stomach for it.
So, how does a regular investor in the UAE or MENA region even begin to approach such a complex field? This isn't about blindly backing a single company. It’s about understanding the entire ecosystem. This is where a platform like Nemo becomes quite useful. Their analysts have done the legwork, identifying a collection of companies that could benefit from this medical shift. In fact, they've grouped these Safer Alzheimer's Treatments into a single theme for users to explore. This approach allows for diversification, spreading the risk beyond a single drug trial. Nemo’s AI-powered analysis provides real-time insights that help make sense of it all, which is a far cry from trying to decipher clinical data on your own. For more detailed company information, one should always consult the Nemo landing page.
Of course, let's not get carried away. All investments carry risk and you may lose money. Biotech is notoriously volatile, and a single regulatory setback can send a stock tumbling. This is not a sure thing. However, the barrier to entry has been lowered. Platforms like Nemo, which is regulated by the ADGM FSRA and partnered with DriveWealth and Exinity, allow you to test the waters without betting the farm. They offer fractional shares, meaning you can start investing in these opportunities with small amounts. This is a sensible way to build a portfolio. The platform earns its keep through spreads, not commissions, which keeps things transparent. For the first time, accessing these kinds of global investment opportunities from the MENA region is straightforward. It’s a compelling proposition, but one that demands a clear head and a full understanding of the risks involved.
View the full Basket:Safer Alzheimer's Treatments
View the full Basket:Safer Alzheimer's Treatments
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article